Breast cancer (BC) is a heterogeneous disease that includes ERα+ (~65%; luminal A and B), HER2+ (~10% HER2+:ERα+; ~10% HER2+:ERα−), and triple negative (~15%; Basal-like, Claudin-low, metaplastic) forms [1]. This evidence concerns the gene ERBB2 and breast carcinoma.